RxDoctor Payments Data

Karen Turner

Nurse Practitioner · O Fallon, MONPI 1154849578

Payments from drug & device makers

$5,689in general payments, 2019–2025

Across 275 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$701
  • Johnson & Johnson$667
  • Takeda Pharmaceuticals U.S.A., Inc.$336
  • Ardelyx, Inc.$327
  • Sanofi$315
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,49096%
  • Education$2004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,689 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$18,721
Medicare patients
137
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$91,794
LinzessLinaclotide31$36,314
Mesalamine11$4,326
Sucralfate13$2,037
Omeprazole110$1,454
CholestyramineCholestyramine (With Sugar)14$1,384
Lubiprostone20$1,302
Pantoprazole Sodium122$1,181
Colestipol Hcl12$840
Famotidine58$590
Dicyclomine Hcl16$526
Esomeprazole Magnesium12$344
Nortriptyline Hcl12$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,576$36,31431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →